Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Blood (2018) 132 (Supplement 1): 3257.

https://doi.org/10.1182/blood-2018-99-115039

Published: 2018

Journal Articles

Description of the First Cases with ADAMTS13 Mutations in Hungary

Marienn Réti, MD, György Sinkovits, MD, Orsolya Cseprekál, MD PhD, Dorottya Csuka, PhD, Ágnes Szilágyi, PhD, Zita Farkas, MD, Zsolt Klucsik, MD, Attila Szederjesi, MSC, László Wágner, MD Prof, György Reusz, MD Prof, Johanna A. Kremer Hovinga, MD Prof, János Rigó, MD Prof, Tamas Masszi, MD Prof., Zoltan Prohászka, MD Prof

Blood (2018) 132 (Supplement 1): 5003.

https://doi.org/10.1182/blood-2018-99-118327

Published: 2018

Journal Articles

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Gergely Varga, MD PhD, Zsolt Nagy, MD PhD, Szabolcs Kosztolányi, MD, Árpád Szomor, MD PhD, Tamás Schneider, MD PhD, Beáta Deák, MD PhD, Krisztina Wolf, MD, Márk Plander, MD PhD, Tamás Szendrei, MD, László Váróczy, MD PhD, Árpád Illés, MD PhD, Árpád Bátai, MD, Mónika Pető, MD, János Fábián, MD, Tamas Masszi, MD PhD, Gabor Mikala, MD PhD

Blood (2017) 130 (Supplement 1): 1865.

https://doi.org/10.1182/blood.V130.Suppl_1.1865.1865

Published: 2017

Journal Articles

First In Europe International Cooperation For Clinical Use Of Wharton Jelly-Derived Mesenchymal Stem Cells

Dominika Gladysz, Katarzyna Pawelec, MD.PhD, Iwona Czaplicka, Magdalena Murzyn, Artur Olkowicz, Tomasz Oldak, Jakub Baran, Dariusz Boruczkowski, MD, PhD

Blood (2013) 122 (21): 2035.

https://doi.org/10.1182/blood.V122.21.2035.2035

Published: 2013

Journal Articles

Immunochemotherapy As Induction (R-CHOP and R-HyperC-VAD/R-MA) in Mantle Cell Lymphoma, a Hungarian Multicenter Open Label Phase II Study (Rituximab [MabThera®] in Mantle Cell Lymphoma, REMENY)

Miklos Udvardy, MD, PhD, Andras Rosta, MD, PhD, Zoltan Gasztonyi, MD, Zita Borbenyi, MD, PhD, Gaspar Radvanyi, MD, Miklos Egyed, MD, PhD, Beata Gasztonyi, MD, PhD, Hajna Losonczy, MD, PhD, Andras Matolcsy, MD, PhD, Agnes H. Andrasfalvy, MD, Tamas J. Schneider, MD

Blood (2012) 120 (21): 4889.

https://doi.org/10.1182/blood.V120.21.4889.4889

Published: 2012

Journal Articles

Results of the Interim Analysis of the “HUSOM” Trial: Hungarian Study of Maintenance After Rituximab Pretreatment, A Multicentre, Phase III, Open-Label Study Evaluating the Benefit of a Long-Term MabThera (rituximab) Maintenance Therapy in Patients with Advance Follicular Lymphoma After Induction of Response (CR(u) or PR) with a MabThera (rituximab)-Containing First Line Regimen

Tamas J. Schneider, MD, Andras Rosta, MD, PhD, Hajna Losonczy, MD, PhD, Gaspar Radvanyi, MD, Gyorgy Ujj, MD, Arpad Illes, MD, PhD, János Jakucs, MD, Zita Borbenyi, MD, PhD

Blood (2011) 118 (21): 2714.

https://doi.org/10.1182/blood.V118.21.2714.2714

Published: 2011

Journal Articles

Fauxcoll gradient

Blood (2010) 115 (13): 2567.

https://doi.org/10.1182/blood-2010-03-272575

Published: 2010

Journal Articles

New Pulmonary Embolism Diagnostic Algorythm and the Thromboprophylaxis in a Hungarian Teaching Hospital.

Miklos Egyed, PhD, Peter Zadori, Peter Rajnics, PhD, Csaba Varga, Anita Horvath, Gyula Horvath, PhD

Blood (2007) 110 (11): 4000.

https://doi.org/10.1182/blood.V110.11.4000.4000

Published: 2007

Journal Articles

Novel Large Deletion Is the Most Frequent Cause of Type 3 von Willebrand Disease in Hungary.

Adrien Mohl, MD, Tamás Masszi, MD, PhD, Eszter Nagy, PhD, Tobias Obser, Florian Oyen, Krisztina Sallai, Imre Bodo, MD, PhD, Reinhard Schneppenheim, MD, PhD

Blood (2006) 108 (11): 1013.

https://doi.org/10.1182/blood.V108.11.1013.1013

Published: 2006

Journal Articles

Striking Coincidence of IgD M-Protein and Translocation t(11;14) in Hungarian Myeloma Patients.

Gabor Mikala, MD, PhD, Emma Adam, Andras Kozma, Balazs Kapas, MD, Sarolta Nahajevszky, MD, Tamas Masszi, MD, PhD

Blood (2006) 108 (11): 5046.

https://doi.org/10.1182/blood.V108.11.5046.5046

Published: 2006

Journal Articles

Prevalence and Clinical Significance of Single and Combined Inherited Thrombophilias.

Hajna Losonczy, MD, PhD, Agnes Nagy, MD, Orsolya Toth, MD, Katalin Balassa, MD, Marianna David, MD, PhD, Marianna Kecskes, MD, Timea Vidra, MD, Arpad Szomor, MD, PhD

Blood (2005) 106 (11): 1632.

https://doi.org/10.1182/blood.V106.11.1632.1632

Published: 2005

Journal Articles

Reprogramming the Transcriptional Response of Chronic Lymphocytic Leukemia (CLL) Cells: Influencing the Temporal Gene Regulatory Network.

Laurent D. Vallat, MD, Corey A. Kemper, BA, Yuhyun Park, PhD, Laura Z. Rassenti, PhD, John W. Fisher, III, PhD, John G. Gribben, MD DSc

Blood (2004) 104 (11): 1128.

https://doi.org/10.1182/blood.V104.11.1128.1128

Published: 2004

Journal Articles

Distinct behavior of mutant triosephosphate isomerase in hemolysate and in isolated form: molecular basis of enzyme deficiency

Ferenc Orosz, Judit Oláh, Marco Alvarez, György M. Keserű, Beáta Szabó, Gábor Wágner, Zoltán Kovári, Margit Horányi, Klára Baróti, Joseph A. Martial, Susan Hollán, Judit Ovádi

Blood (2001) 98 (10): 3106–3112.

https://doi.org/10.1182/blood.V98.10.3106

Published: 2001

NARROW

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Description of the First Cases with ADAMTS13 Mutations in Hungary

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

First In Europe International Cooperation For Clinical Use Of Wharton Jelly-Derived Mesenchymal Stem Cells

Immunochemotherapy As Induction (R-CHOP and R-HyperC-VAD/R-MA) in Mantle Cell Lymphoma, a Hungarian Multicenter Open Label Phase II Study (Rituximab [MabThera®] in Mantle Cell Lymphoma, REMENY)

Fauxcoll gradient

New Pulmonary Embolism Diagnostic Algorythm and the Thromboprophylaxis in a Hungarian Teaching Hospital.

Novel Large Deletion Is the Most Frequent Cause of Type 3 von Willebrand Disease in Hungary.

Striking Coincidence of IgD M-Protein and Translocation t(11;14) in Hungarian Myeloma Patients.

Prevalence and Clinical Significance of Single and Combined Inherited Thrombophilias.

Reprogramming the Transcriptional Response of Chronic Lymphocytic Leukemia (CLL) Cells: Influencing the Temporal Gene Regulatory Network.

Distinct behavior of mutant triosephosphate isomerase in hemolysate and in isolated form: molecular basis of enzyme deficiency

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only